ReviewBiosensors2025
The Potential of Nanopore Technologies in Peptide and Protein Sensing for Biomarker Detection.
Review in Biosensors, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- RNA-DNA Fusomer Fibers With Customizable Physicochemical, Mechanical, and Biological Properties for Next-Generation Therapeutics.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Engineered Protein Modification: A New Paradigm for Enhancing Biosensing Sensitivity and Diagnostic Accuracy.Biosensors · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The increasing demand for high-throughput, real-time, and single-molecule protein analysis in precision medicine has propelled the development of novel sensing technologies. Among these, nanopore-based methods have garnered significant attention for their unique capabilities, including label-free detection, ultra-sensitivity, and the potential for miniaturization and portability. Originally designed for nucleic acid sequencing, nanopore technology is now being adapted for peptide and protein analysis, offering promising applications in biomarker discovery and disease diagnostics. This review examines the latest advances in biological, solid-state, and hybrid nanopores for protein sensing, focusing on their ability to detect amino acid sequences, structural variants, post-translational modifications, and dynamic protein-protein or protein-drug interactions. We critically compare these systems to conventional proteomic techniques, such as mass spectrometry and immunoassays, discussing advantages and persistent technical challenges, including translocation control and signal deconvolution. Particular emphasis is placed on recent advances in protein sequencing using biological and solid-state nanopores and the integration of machine learning and signal-processing algorithms that enhance the resolution and accuracy of protein identification. Nanopore protein sensing represents a disruptive innovation in biosensing, with the potential to revolutionize clinical diagnostics, therapeutic monitoring, and personalized healthcare.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.